Does Rallies show Form 4 insider transactions for LFCR?

Yes. Rallies tracks LFCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LFCR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LFCR. It does not provide personalized investment advice.

LFCR (Lifecore Biomedical, Inc. Common Stock) Stock Analysis - Insider Trades

Lifecore Biomedical, Inc. Common Stock (LFCR) is a publicly traded Healthcare sector company. As of May 21, 2026, LFCR trades at $4.57 with a market cap of $164.29M and a P/E ratio of -3.53. LFCR moved +4.34% today. Year to date, LFCR is -41.41%; over the trailing twelve months it is -31.07%. Its 52-week range spans $3.63 to $8.98. Analyst consensus is strong buy with an average price target of $6.67. Rallies surfaces LFCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LFCR stock inside the company?

Recent LFCR insider activity includes English Aron R. sold 150.42K, English Aron R. sold 1.14M, English Aron R. sold 96.14K, English Aron R. sold 12.33K, and English Aron R. sold 45.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LFCR Key Metrics

Key financial metrics for LFCR
Metric	Value
Price	$4.57
Market Cap	$164.29M
P/E Ratio	-3.53
EPS	$-1.27
Dividend Yield	0.00%
52-Week High	$8.98
52-Week Low	$3.63
Volume	0
Avg Volume	0
Revenue (TTM)	$128.87M
Net Income	$-38.72M
Gross Margin	31.27%

Recent LFCR Insider Trades

English Aron R. sold 150.42K (~$1.07M) on May 28, 2025.
English Aron R. sold 1.14M (~$7.41M) on May 27, 2025.
English Aron R. sold 96.14K (~$649.39K) on May 23, 2025.
English Aron R. sold 12.33K (~$86.35K) on May 13, 2025.
English Aron R. sold 45.70K (~$321.43K) on May 12, 2025.

Latest LFCR News

Lifecore Biomedical Q1 Revenue Falls 34% to $23.2M, Reaffirms $120M-$125M Guidance — May 6, 2026
Lifecore Biomedical Q1 Preview: $25.96M Revenue, 17.2% Upside — Apr 30, 2026
Lifecore Scores Fourth Site Transfer in Five Months and Expands Ophthalmic Manufacturing — Mar 26, 2026
Lifecore Biomedical Q4 Revenue Up 10% to $35.7M, 2026 Guide $120–125M — Mar 16, 2026
Lifecore Signs Second Agreement to Supply DT-001 Batches for 2026 Phase 2 Acne Trials — Mar 4, 2026

LFCR Analyst Consensus

4 analysts cover LFCR: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.67.

Common questions about LFCR

Who is trading LFCR stock inside the company?: Recent LFCR insider activity includes English Aron R. sold 150.42K, English Aron R. sold 1.14M, English Aron R. sold 96.14K, English Aron R. sold 12.33K, and English Aron R. sold 45.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LFCR?: Yes. Rallies tracks LFCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LFCR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LFCR. It does not provide personalized investment advice.